Abstract
INITIAL EXPERIENCE WITH THE OXYTOCIN ANTAGONIST ATOSIBAN FOR PRETERM LABOR IN A TERTIARY CARE CENTRE: PROSPECTIVE OBSERVATIONAL COHORT STUDY

*Bhatt Reema K., Dr. Anupam Kapur, Dr. Shikha Choudhary, Dr. Sanjay Sharma and Dr. Pranjali Dwivewdi

ABSTRACT

Background: Preterm labor(PTL) leads to alarming situations and challenges for doctors and is a distressing condition for pregnant women and their families. Therapy with uterospecific tocolytic Atosiban is a common practice nowadays due its high efficacy and safety evidences in inhibiting the early uterine contractions thus delaying the delivery, permitting better fetal growth and reducing the newborn mortality and morbidity. Aims: To evaluate efficacy and safety of uterospecific tocolytic Atosiban in pregnant women with PTL. Settings and Design: Prospective observational cohort study was conducted in the Department of Obstetrics and Gynecology, Tertiary Care Hospital, North India. Methods and Material: 150 singleton/twin pregnant women were administered Atosiban intravenously for 48 hours. Efficacy was determined by the percentage of women who remained undelivered after therapy initiation up to 48 hours. Safety was assessed by the numbers of maternal, fetal or neonatal adverse events (AE) reported. Statistical analysis used: Intent-to-treat statistical analysis was used. Descriptive statistics were used to represent the data [expressed as Mean ± SD, N (%)]. Results: Atosiban successfully delayed the preterm deliveries by ≥ 48 hours in 146 (97.3 %) pregnant women, of which 140 pregnancies remained undelivered for ˃7 days and some of them even up to 5 weeks. No maternal and fetal AE were reported, 01 neonatal death occurred due to sepsis. Conclusion: Based on our initial clinical experience, we conclude that Atosiban is an effective and well tolerated drug in prolonging the duration of pregnancy in women with PTL.

Keywords: Atosiban, Gestation, Labor, Oxytocin, Pregnant, Preterm, Prolongation, Tocolytic.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tanima Debnath Sarkar

Download Article : Click here

News & Updation

  • EJBPS: OCTOBER ISSUE PUBLISHED

    OCTOBER 2021 Issue has been successfully launched on 1 October 2021

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT